160 related articles for article (PubMed ID: 37296430)
21. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.
Kohestani K; Månsson M; Arnsrud Godtman R; Stranne J; Wallström J; Carlsson S; Hellström M; Hugosson J
Scand J Urol; 2021 Apr; 55(2):116-124. PubMed ID: 33612068
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer and prostate-specific antigen testing in New South Wales.
Smith DP; Supramaniam R; Marshall VR; Armstrong BK
Med J Aust; 2008 Sep; 189(6):315-8. PubMed ID: 18803534
[TBL] [Abstract][Full Text] [Related]
24. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
Heijnsdijk EA; Denham D; de Koning HJ
Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
[TBL] [Abstract][Full Text] [Related]
25. Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial.
Carlsson SV; Arnsrud Godtman R; Pihl CG; Vickers A; Lilja H; Hugosson J; Månsson M
Eur Urol; 2023 Feb; 83(2):103-109. PubMed ID: 36334968
[TBL] [Abstract][Full Text] [Related]
26. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
27. Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial.
Auvinen A; Määttänen L; Finne P; Stenman UH; Aro J; Juusela H; Rannikko S; Tammela TL; Hakama M
Int J Cancer; 2004 Oct; 111(6):940-3. PubMed ID: 15300807
[TBL] [Abstract][Full Text] [Related]
28. Opportunistic prostate cancer screening: A population-based analysis.
Matti B; Zargar-Shoshtari K
Urol Oncol; 2020 May; 38(5):393-400. PubMed ID: 31952998
[TBL] [Abstract][Full Text] [Related]
29. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer.
Heijnsdijk EA; der Kinderen A; Wever EM; Draisma G; Roobol MJ; de Koning HJ
Br J Cancer; 2009 Dec; 101(11):1833-8. PubMed ID: 19904272
[TBL] [Abstract][Full Text] [Related]
30. Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial.
Evans R; Joseph-Williams N; Edwards A; Newcombe RG; Wright P; Kinnersley P; Griffiths J; Jones M; Williams J; Grol R; Elwyn G
J Med Internet Res; 2010 Aug; 12(3):e27. PubMed ID: 20693148
[TBL] [Abstract][Full Text] [Related]
31. Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Kovac E; Carlsson SV; Lilja H; Hugosson J; Kattan MW; Holmberg E; Stephenson AJ
JAMA Netw Open; 2020 Jan; 3(1):e1919284. PubMed ID: 31940039
[TBL] [Abstract][Full Text] [Related]
32. Shared decision making in prostate-specific antigen testing: the effect of a mailed patient flyer prior to an annual exam.
Landrey AR; Matlock DD; Andrews L; Bronsert M; Denberg T
J Prim Care Community Health; 2013 Jan; 4(1):67-74. PubMed ID: 23799692
[TBL] [Abstract][Full Text] [Related]
33. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
Lane JA; Hamdy FC; Martin RM; Turner EL; Neal DE; Donovan JL
Eur J Cancer; 2010 Nov; 46(17):3095-101. PubMed ID: 21047592
[TBL] [Abstract][Full Text] [Related]
34. Cost implications of PSA screening differ by age.
Rao K; Liang S; Cardamone M; Joshu CE; Marmen K; Bhavsar N; Nelson WG; Ballentine Carter H; Albert MC; Platz EA; Pollack CE
BMC Urol; 2018 May; 18(1):38. PubMed ID: 29743049
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
36. Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.
Hewlett S; Almeida C; Ambler N; Blair PS; Choy E; Dures E; Hammond A; Hollingworth W; Kadir B; Kirwan J; Plummer Z; Rooke C; Thorn J; Turner N; Pollock J
Health Technol Assess; 2019 Oct; 23(57):1-130. PubMed ID: 31601357
[TBL] [Abstract][Full Text] [Related]
37. A Cost-Utility Analysis of Prostate Cancer Screening in Australia.
Keller A; Gericke C; Whitty JA; Yaxley J; Kua B; Coughlin G; Gianduzzo T
Appl Health Econ Health Policy; 2017 Feb; 15(1):95-111. PubMed ID: 27757918
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
[TBL] [Abstract][Full Text] [Related]
39. Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.
Nordström T; Annerstedt M; Glaessgen A; Carlsson S; Clements M; Abbadi A; Grönberg H; Jäderling F; Eklund M; Discacciati A
JAMA Netw Open; 2024 Feb; 7(2):e2354577. PubMed ID: 38324313
[TBL] [Abstract][Full Text] [Related]
40. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
Ross KS; Carter HB; Pearson JD; Guess HA
JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
